Anti-CD38 monoclonal antibody that targets CD38 on plasma cells, inducing ADCC, CDC, and apoptosis.
Human IgG1κ monoclonal antibody against CD38 that binds CD38 on malignant plasma cells, inducing antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), antibody-dependent cellular phagocytosis (ADCP), and direct apoptosis; also depletes CD38+ immunosuppressive cells (Tregs, Bregs, MDSCs) to enhance anti-tumor immunity.
YES
DIRECT
Anti-CD38 antibody binds CD38 on target cells and triggers ADCC (NK cells), complement-mediated lysis (CDC), antibody-dependent cellular phagocytosis (ADCP), and can induce direct apoptosis.
A subcutaneous bispecific T cell–engaging antibody that binds CD20 on malignant B cells and engages CD8/TCR on T cells, redirecting cytotoxic T cells to CD20+ targets to induce immune synapse formation, TCR signaling, cytokine release, and perforin/granzyme-mediated killing, leading to depletion of CD20+ B cells in CD20+ mature B-cell malignancies (LBCL, FL, MCL, CLL/SLL).
An IgG-like T cell–engaging antibody that binds CD20 on malignant B cells and CD3/CD8 on CD8+ T cells, crosslinking them to form an immune synapse, activating TCR signaling, cytokine release, and perforin/granzyme-mediated killing to deplete CD20+ B cells in B-cell malignancies.
YES
DIRECT
AZD5492 bridges CD20 on B cells with CD3/CD8 on CD8+ T cells, forming an immune synapse that activates TCR signaling and triggers perforin/granzyme-mediated killing of CD20+ cells.
A subcutaneous bispecific T cell–engaging antibody that binds CD20 on malignant B cells and engages CD8/TCR on T cells, redirecting cytotoxic T cells to CD20+ targets to induce immune synapse formation, TCR signaling, cytokine release, and perforin/granzyme-mediated killing, leading to depletion of CD20+ B cells in CD20+ mature B-cell malignancies (LBCL, FL, MCL, CLL/SLL).
An IgG-like T cell–engaging antibody that binds CD20 on malignant B cells and CD3/CD8 on CD8+ T cells, crosslinking them to form an immune synapse, activating TCR signaling, cytokine release, and perforin/granzyme-mediated killing to deplete CD20+ B cells in B-cell malignancies.
NO
INDIRECT
AZD5492 engages CD3 (and CD8) on T cells to activate them to kill CD20+ B cells via perforin/granzyme; CD3+ T cells are effectors, not killed by the drug.
A subcutaneous bispecific T cell–engaging antibody that binds CD20 on malignant B cells and engages CD8/TCR on T cells, redirecting cytotoxic T cells to CD20+ targets to induce immune synapse formation, TCR signaling, cytokine release, and perforin/granzyme-mediated killing, leading to depletion of CD20+ B cells in CD20+ mature B-cell malignancies (LBCL, FL, MCL, CLL/SLL).
An IgG-like T cell–engaging antibody that binds CD20 on malignant B cells and CD3/CD8 on CD8+ T cells, crosslinking them to form an immune synapse, activating TCR signaling, cytokine release, and perforin/granzyme-mediated killing to deplete CD20+ B cells in B-cell malignancies.
NO
INDIRECT
AZD5492 bridges CD8/CD3 on T cells to CD20 on B cells, activating T cells to release perforin/granzyme and kill CD20+ B cells; CD8+ T cells are not killed but serve as effectors.
CD44v6-targeting monoclonal antibody used as the targeting moiety for radioimmunotherapy; binds the CD44v6 isoform on tumor cells to deliver the attached radionuclide.
A CD44v6-targeting monoclonal antibody labeled with lutetium-177 that binds CD44v6 on tumor cells and delivers localized beta radiation, inducing DNA damage (including double-strand breaks) and tumor cell death, with a cross-fire effect to nearby CD44v6-positive cells.
YES
DIRECT
A Lu-177–labeled anti-CD44v6 antibody binds CD44v6 and delivers beta radiation to the bound cell, causing DNA double-strand breaks and cell death; cross-fire can also kill nearby cells.